No Data
No Data
joinn laboratories (603127.SH): cumulatively repurchased 0.2806% of shares
On October 8, GeLongHui announced that, as of September 30, 2024, the company had cumulatively repurchased 2,103,100 A-shares through centralized bidding trade, accounting for 0.2806% of the total shares outstanding on the announcement date. The highest repurchase price was RMB 18.15 per share, the lowest repurchase price was RMB 13.20 per share, and the total amount used for the repurchase was RMB 33,195,984.40 (excluding transaction fees).
[Brokerage Focus] China Post Securities expects the pharmaceutical sector to continue to rise uniformly, suggesting prioritizing the layout of various segmented sectors and leading companies in the first and second tiers during the general rise phase.
Golden Herald Financial News | China Post Securities stated that since the end of September, the pharmaceutical sector has been boosted by the national comprehensive incremental policy, solidly promoting the economy towards a higher-quality structure under the heavy bullish push, leading to a rapid rebound of the index by about 29%, reversing the continuous decline of nearly 4 years. Looking at the current PE (TTM), A-share pharmaceuticals are at 32 times, and Hong Kong stocks at 23 times. The previous continuous decline has already deviated from the fundamentals. The bank believes that the increase in market risk appetite will accelerate the sector's valuation repair. As of H1 2024, the institutions hold a 7.3% stake in the CSI SWS Health Care Index sector, which, although slightly lower than the end of 2023, still remains at a historically high level, indicating a general positive sentiment among institutions.
Trending Industry Today: JOINN Leads Gains In CRO Stocks
Revenues Not Telling The Story For Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) After Shares Rise 28%
JOINN: 2024 Interim Report
HK stocks anomaly | CRO concept stocks continue to rise, hindered by the enactment of the Biosecurity Law, top companies' investment sentiment is expected to marginally improve.
The CRO concept stocks continue to rise. As of the time of publication, Tigermed (03347) rose by 9.28%, to 31.2 Hong Kong dollars; Pharmaron (03759) rose by 4.85%, to 11.24 Hong Kong dollars; and Joinn Laboratories (06127) rose by 4.8%, to 7.64 Hong Kong dollars.
No Data
No Data